This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will ProQR Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor ProQR Therapeutics.
ProQR Therapeutics Enters Oversold Territory
by Zacks Equity Research
ProQR Therapeutics N.V. (PRQR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
by Zacks Equity Research
Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.
Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
by Zacks Equity Research
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
Mallinckrodt Enrolls First Patient in Liver Disease Study
by Zacks Equity Research
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
ProQR (PRQR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of 24.44% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of -13.89% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
ProQR Initiates Dosing in Phase II/III Eye Disorder Study
by Zacks Equity Research
ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus
by Zacks Equity Research
The Medicines Company (MDCO) suffers a wider-than-expected loss in Q4. At the same time, the company fails to generate revenues.
Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
by Zacks Equity Research
Agios' (AGIO) label expansion filing eyes an approval of Tibsovo for newly diagnosed acute myeloid leukemia patients with an IDH1 mutation. The drug also gets a priority review tag from the FDA.
Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
by Zacks Equity Research
Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.
Company News For Jan 3, 2019
by Zacks Equity Research
Companies in the news are: GOOGL, TSLA, PRQR, OHI and MRT
Best Sector of 2018 and its Hit ETFs & Stocks
by Sweta Killa
Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.
ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of 46.15% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
by Zacks Equity Research
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
3 Small Biotech Stocks That Almost Doubled in Past Month
by Zacks Equity Research
We take a look at three biotech stocks, prices of which have almost doubled in the past month.
ProQR Up More Than 120% on Favorable Eye Disorder Study Data
by Zacks Equity Research
ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
Will ProQR Therapeutics (PRQR) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in ProQR Therapeutics N.V. (PRQR)
ProQR's Genetic Disorder Candidate Gets Orphan Drug Status
by Zacks Equity Research
ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.
ProQR's QRX-421 Gets Orphan Drug Designation from FDA and EMA
by Zacks Equity Research
ProQR Therapeutics's (PRQR) pipeline candidate, QRX-421, has received orphan drug designation from the FDA and European Medicines Agency.
ProQR's Usher Syndrome Candidate Gets Orphan Drug Status
by Zacks Equity Research
ProQR Therapeutics N.V. (PRQR) announced that its key pipeline candidate, QRX-411, has been granted orphan drug designation by the FDA and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa.
Can The Uptrend Continue for ProQR Therapeutics (PRQR)?
by Zacks Equity Research
Investors certainly have to be happy with ProQR Therapeutics NV (PRQR) and its short term performance